Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Drug Price Reform Takes Shape: Price Ceilings Out, Reimbursement Caps In

This article was originally published in PharmAsia News

Executive Summary

China’s NDRC plans to substitute reimbursement caps for maximum ceiling prices on drugs to narrow the difference between prices of branded and domestic generics. For imported patented drugs, international reference pricing is under consideration.

You may also be interested in...



One Year On: WHO Probe In Wuhan, Mixed Vaccine Results For Sinovac

One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.

Chi-Med's Surufatinib, Generic Ibrance Among Latest China Approvals

China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.

BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal

BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.

Topics

Related Companies

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel